At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Market Closed 05-22 16:00:00 EDT
0.9500
+0.0200
+2.15%
盘后0.9600
+0.0100+1.05%
19:54 EDT
High0.9699Low0.8905Vol189.78K
Open0.9000D1 Closing0.9300Amplitude8.54%
Mkt Cap11.76MTradable Cap8.26MTotal Shares12.38M
T/O173.49KT/O Rate2.18%Tradable Shares8.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aprea Therapeutics - Files for Resale of up to 5.5 Mln Shares by Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  05-16
Aprea Therapeutics - Files for Resale of up to 5.5 Mln Shares by Selling Stockholders - SEC Filing
Aprea Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-13
Aprea Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall
Reuters  ·  05-13
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
THOMSON REUTERS  ·  05-13
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Aprea Therapeutics Q1 EPS USD -0.22
THOMSON REUTERS  ·  05-13
Aprea Therapeutics Q1 EPS USD -0.22
Top News Today: Stocks Mixed, Oil Rises After Hot Inflation Data
Dow Jones  ·  05-13
Top News Today: Stocks Mixed, Oil Rises After Hot Inflation Data
Top News Today/Canada: Pet Valu Trims Outlook Amid Squeezed Margins
Dow Jones  ·  05-13
Top News Today/Canada: Pet Valu Trims Outlook Amid Squeezed Margins
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Reuters  ·  05-08
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Aprea Therapeutics, Inc. :  Oppenheimer Initiates Coverage With Outperform Rating and Target Price $5
THOMSON REUTERS  ·  05-07
Aprea Therapeutics, Inc. :  Oppenheimer Initiates Coverage With Outperform Rating and Target Price $5
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
TIPRANKS  ·  04-23
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
Aprea to present early Phase 1 data for WEE1 inhibitor APR-1051 at ASCO 2026
Reuters  ·  04-21
Aprea to present early Phase 1 data for WEE1 inhibitor APR-1051 at ASCO 2026
Aprea Therapeutics to Provide Clinical Update on Acesot-1051 Phase 1 Trial Evaluating Wee1 Inhibitor, Apr-1051, at Asco 2026 Annual Meeting
THOMSON REUTERS  ·  04-21
Aprea Therapeutics to Provide Clinical Update on Acesot-1051 Phase 1 Trial Evaluating Wee1 Inhibitor, Apr-1051, at Asco 2026 Annual Meeting
Aprea Therapeutics announces annual shareholder meeting via webcast
Reuters  ·  04-20
Aprea Therapeutics announces annual shareholder meeting via webcast
Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)
TIPRANKS  ·  04-07
Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)
Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds
Reuters  ·  04-01
Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
THOMSON REUTERS  ·  04-01
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $1.2 From $4
THOMSON REUTERS  ·  03-31
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $1.2 From $4
BRIEF-Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051
Reuters  ·  03-30
BRIEF-Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051
Aprea Therapeutics announces oversubscribed private placement raising about $30 million
Reuters  ·  03-30
Aprea Therapeutics announces oversubscribed private placement raising about $30 million
Aprea reports confirmed partial response for APR-1051 in Phase 1 ACESOT-1051 trial
Reuters  ·  03-30
Aprea reports confirmed partial response for APR-1051 in Phase 1 ACESOT-1051 trial

Introduction

Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--